Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 3-7

  Serebruany, Victor L ^a   Pokov, Alex N ^a   Fortmann, Seth D ^a   DiNicolantonio, James J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Wegmans Pharmacy   (United States)

Author keywords

Cangrelor; Clinical trials; Efficacy; Mortality; Myocardial infarction; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL;

BLEEDING; DEATH; DRUG EFFICACY; DYSPNEA; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION;

CANGRELOR; CLINICAL TRIALS; EFFICACY; MORTALITY; MYOCARDIAL INFARCTION; STENT THROMBOSIS;

ADENOSINE MONOPHOSPHATE; BLOOD PLATELETS; DATA INTERPRETATION, STATISTICAL; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STENTS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891876288     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0631     Document Type: Review

References (19)

1. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009; 7: 1195-1201.
2. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
3. Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010; 50: 27-35.
4. Angiolillo DJ, Firstenberg MS, Price MJ, et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.
5. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
6. Bhatt DL, Lincoff AM, Gibson CM, et al.; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
7. Bhatt DL, Stone GW, Mahaffey KW, et al.; the CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013; 368: 1303-1313.
8. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012; 163: 768-776.
9. Bhatt DH. CHAMPION PHOENIX Trial, main results. ACC 2013, late-breaking trials, presented March 10, 2013.
10. Shelton R, Eftychiou C, Somers K, et al. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population. EuroIntervention 2013; 9: 118-124.
11. Dangas GD, Claessen BE, Mehran R, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012; 59: 1752-1759.
12. Brener SJ, Cristea E, Kirtane AJ, et al. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 2013; 6: 36-43.
13. Serebruany VL, Aradi D, Kim MH, et al. Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials. Int J Cardiol 2013; in press.
14. Wiviott SD, Braunwald E, McCabe CH, et al.; the TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
15. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373(9665): 723-31.
16. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
17. Serebruany VL. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
18. Ticagrelor Secondary Review. Available for download at http: //www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220192.pdf.
19. FDA ticagrelor review of complete response-drug approval package. http://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2011/022433Orig1s000TOC.cfm. Assessed March 24, 2013.